Aarti Drugs Limited has informed the Exchange regarding Financial results for the quarter and year ended March 31, 2025 .
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 18.4 pts more than Nifty Microcap 250 and 19.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs has announced its audited financial results for the quarter and full year ended March 31, 2025, with the Board approving the same on May 6, 2025. Standalone total income for FY25 stood at approximately Rs. 2,26,691 lakhs, up from around Rs. 2,17,365 lakhs in FY24, indicating modest single-digit revenue growth. Standalone profit after tax for FY25 came in at about Rs. 14,188 lakhs, with consolidated PAT around Rs. 16,810 lakhs. The company reported exceptional items of Rs. 2,000 lakhs in Q4 standalone results. The statutory auditor Gokhale & Sathe issued an un-modified (clean) opinion on both standalone and consolidated results. Additionally, M/s GMVP & Associates LLP was re-appointed as Cost Auditor for FY 2025-26. Operating cash flow remained healthy at roughly Rs. 35,892 lakhs (standalone), and the company completed its Rs. 59.85 crore share buyback in September 2024, reducing paid-up share capital accordingly.
Clean audit opinion and positive operating cash flow are positive signals, but the modest revenue growth and presence of exceptional items in Q4 suggest mixed underlying performance. The buyback completion supports earnings per share going forward, and re-appointment of the cost auditor is a routine compliance matter with no material impact.